Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
_256_384.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Subscribe To Our Newsletter & Stay Updated
